Non-nucleoside reverse transcriptase inhibitor outcomes among combination antiretroviral therapy-treated adults in Botswana

AIDS

Volumn 24, Issue SUPPL. 1, 2010, Pages

  Wester, C William ^a,b,d   Thomas, Ann Muir ^b   Bussmann, Hermann ^a,b   Moyo, Sikhulile ^c   Makhema, Joseph M ^b   Gaolathe, Tendani ^b,c   Novitsky, Vladimir ^a,b   Essex, Max ^a,b   Degruttola, Victor ^b   Marlink, Richard G ^a,b  

^a BOTSWANA HARVARD AIDS INSTITUTE PARTNERSHIP   (Botswana)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c Department of HIV AIDS Prevention and Care   (Botswana)

^d VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

HAART; HIV AIDS; Nevirapine versus efavirenz; Non nucleoside reverse transcriptase inhibitors; Randomized clinical trial; Sub Saharan Africa

Indexed keywords

COTRIMOXAZOLE; DIDANOSINE; DIDANOSINE PLUS EFAVIRENZ PLUS ZIDOVUDINE; DIDANOSINE PLUS NEVIRAPINE PLUS ZIDOVUDINE; EFAVIRENZ; EFAVIRENZ PLUS LAMIVUDINE PLUS STAVUDINE; EFAVIRENZ PLUS LAMIVUDINE PLUS ZIDOVUDINE; ISONIAZID; LAMIVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS ZIDOVUDINE; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; UNCLASSIFIED DRUG; ZIDOVUDINE;

ADULT; ANEMIA; ANTIVIRAL RESISTANCE; ARTICLE; BOTSWANA; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; COMMUNITY CARE; CONTROLLED CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; FACTORIAL DESIGN; FEMALE; FEVER; HEADACHE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERSENSITIVITY REACTION; LACTIC ACIDOSIS; LIPOATROPHY; LIPODYSTROPHY; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; NEPHROTOXICITY; NEUTROPENIA; OPPORTUNISTIC INFECTION; PANCREATITIS; PANCYTOPENIA; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RISK ASSESSMENT; TREATMENT OUTCOME; VERTICAL TRANSMISSION; VIRUS VIRULENCE; VOMITING;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BOTSWANA; DRUG THERAPY, COMBINATION; FAMILY PLANNING SERVICES; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; PREGNANCY; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT OUTCOME;

EID: 74249089760     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/01.aids.0000366080.91192.55     Document Type: Article

References (38)

1. World Health Organization. Priority interventions: HIV/AIDS prevention, treatment and care in the health sector, September 2008. Geneva: World Health Organization; 2008. ISBN 978 92 4 159696 1
2. Pan American Health Organization. Guidelines for the implementation ofreliable and efficient diagnostic HIV testing, region of the Americas. 2008. Available at: http://www.paho.org/English/ ad/fch/ai/lab-guide-eng.pdf. Accessed: 7 November 2009.
3. Djomand G, Roels T, Ellerbrock T, Hanson D, Diomande F, Monga B, et al. Virologic and immunologic outcomes and programmatic challenges of an antiretroviral treatment pilot project in Abidjan, Cote d'Ivoire. AIDS 2003; 17 (Suppl. 3):S5-S15.
4. Laurent C,Diakhaté N, Gueye NF, Touré MA, Sow PS, Faye MA, et al. The Senegalese government's highly active antiretroviral therapy initiative: an 18-month follow-up study. AIDS 2002; 16:1363-1370.
5. Weidle PJ, Malamba S, Mwebaze R, Sozi C, Rukundo G, Downing R, et al. Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients' response, survival, and drug resistance. Lancet 2002; 360:34-40.
6. Coetzee D, Hildebrand K, Boulle A, Maartens G, Louis F, Labatala V, et al. Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. AIDS 2004; 18:887-895.
7. Wester CW, Kim S, BussmannH,Avalos A, Ndwapi N, Peter TF, et al. Initial response to highly active antiretroviral therapy in HIV-1C-infected adults in a public sector treatment program in Botswana. J Acquir Immune Defic Syndr 2005; 40:336-343.
8. Ferradini L, Jeannin A, Pinoges L, Izopet J, Odhiambo D, Mankhambo L, et al. Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment. Lancet 2006; 367:1335-1342.
9. Harries AD, Gomani P, Teck R, de Teck OA, Bakali E, Zachariah R, et al. Monitoring the response to antiretroviral therapy in resource-poor settings: the Malawi model. Trans R Soc Trop Med Hyg 2004; 98:695-701.
10. Bussmann H, Wester CW, Thomas A, Novitsky V, Okezie R, Muzenda T, et al. Five-year outcomes of initial patients treated in Botswana's National Antiretroviral Treatment Program. AIDS 2008; 22:1-9.
11. Stringer JS, Zulu I, Levy J, Stringer EM, Mwango A, Chi BH, et al. Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. JAMA 2006; 296:782-793.
12. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. 3 November 2008; 1-139. Available at: http:// www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed: 7 November 2009. pp. 26-29.
13. Robbins GK, De Gruttola V, Shafer RW, Smeaton LM, Snyder SW, Pettinelli C, et al. Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med 2003; 349:2293-2303.
14. Staszewski S, Morales-Ramirez J, Tashima KT, Rachlis A, Skiest D, Stanford J, et al. Efavirenz plus zidovudine and lamuvidine, efavirenz plus indinavir, and indinavir plus zidovudine and lamuvidine in the treatment of HIV-1 infection in adults. N Engl J Med 1999; 341:1865-1873.
15. O'Brien ME, Clark RA, Besch CL, Myers L, Kissinger P. Patterns and correlates of discontinuation of the initial HAART regimen in an urban outpatient cohort. J Acquir Immune Defic Syndr 2003; 34:407-414.
16. Keiser O, Fellay J, Opravil M, Hirsch HH, Hirschel B, Bernas-coni E, et al. Adverse events to antiretrovirals in the Swiss HIV Cohort Study: effect on mortality and treatment modification. Antiviral Ther 2007; 12:1157-1164.
17. Baylor MS, Johann-Liang R. Hepatotoxicity associated with nevirapine use. J Acquir Immune Defic Syndr 2004; 35:538-539.
18. Dieterich DT, Robinson PA, Love J, Stern JO. Drug-induced liver injury associated with the use of nonnucleoside reverse-transcriptase inhibitors. Clin Infect Dis 2004; 38 (Suppl. 2):S80-S89.
19. LockmanS,Shapiro RL, Smeaton M,WesterC,ThiorI,Stevens L, et al. Responsetoantiretroviraltherapy afterasingle,peripartum dose of nevirapine. N Engl J Med 2007; 356:135-147.
20. van Leth F, Phanuphak P, Ruxrungtham K, Baraldi E, Miller S, Gazzard B, et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet 2004; 363:1253-1263.
21. van den Berg-Wolf M, Hullsiek KH, Peng G, Kozal MJ, Novak RM, Chen L, et al. Virologic, immunologic, clinical, safety, and resistance outcomes from a long-term comparison of efavir-enz-based versus nevirapine-based antiretroviral regimens as initial therapy in HIV-1 infected persons. HIV Clin Trials 2008; 9:324-336.
22. Nachega JB, Hislop M, Dowdy DW, Gallant JE, Chaisson RE, Regensberg L, Maartens G. Efavirenz versus nevirapine-based initial treatment of HIV infection: clinical and virological outcomes in Southern African adults. AIDS 2008; 22:2117-2125.
23. Bussmann H, Wester CW, Wester CN, Lekoko B, Okezie O, Thomas AM, et al. Pregnancy rates and birth outcomes among women on efavirenz-containing HAART in Botswana. J Acquir Immune Defic Syndr 2007; 45:269-273.
24. Hogg R, May M, Philips AN, Costagliola D, Sterne JAC, Sabin CA, et al. ART-CC Analysis and Writing Committee members. Rates of disease progression according to initial highly active antiretroviral therapy regimen: a collaborative analysis of 12 prospective cohort studies. J Infect Dis 2006; 194:612-622.
25. Hughes MD. Initial treatment of HIV infection: randomized trials with clinical end points are still needed. J Infect Dis 2006; 194:542-544.
26. Ministry of Health, Botswana. Guidelines on antiretroviral treatment, 2002 version. Gaborone, Botswana: Ministry of Health; 2002.
27. Ministry of Health, Botswana. Guidelines on antiretroviral treatment, 2005 version. Gaborone, Botswana: Ministry of Health; 2005.
28. Weverling GJ, Lange JM, Jurriaans S, Prins JM, Lukashov VV, Notermans DW, et al. Alternative multidrug regimen provides improved suppression of HIV-1 replication over triple therapy. AIDS 1998; 12:F117-F122.
29. Polis MA, Sidorov IA, Yoder C, Jankelevich S, Metcalf J, Mueller BU, et al. Correlation between reduction in plasma HIV-1 RNA concentration 1 week after start of antiretroviral treatment and longer-term efficacy. Lancet 2001; 358:1760-1765.
30. Ghani AC, Ferguson NM, Fraser C, Donnelly CA, Danner S, Reiss P, et al. Viral replication under combination antiretroviral therapy: a comparison of four different regimens. J Acquir Immune Defic Syndr 2002; 30:167-176.
31. Maggiolo F, Migliorino M, Pirali A, Pravettoni G, Caprioli S, Suter F. Duration of viral suppression in patients on stable therapy for HIV-1 infection is predicted by plasma HIV RNA level after 1 month of treatment. J Acquir Immune Defic Syndr 2000; 25:36-43.
32. Division of AIDS, NIAID. Division of AIDS table for grading severity of adult adverse experiences. Rockville, MD: National Institute of Allergy and Infectious Diseases; 1994
33. Division of AIDS, NIAID. Division of AIDS table for grading severity of adult adverse experiences. Rockville, MD: National Institute of Allergy and Infectious Diseases; 2004.
34. Boehringer Ingelheim Pharmaceuticals, Inc. "Important and urgent advance information". Dear Doctor/Dear Pharmacist letter; entitled "Re: Identification of patients at particular risk of serious hepatic and cutaneous reactions associated with Viramune (nevirapine) 200mg tablets and 50mg/5ml oral suspension." dated 11 May 2004; and signed by Mark Hopley, MD, Medical Director.
35. Holm S. A simple sequentially rejective multiple test procedure. Scand J Statistics 1979; 6:65-70.
36. Rhee S-Y, Gonzales MJ, Kantor R, Betts BJ, Ravela J, Shafer RW. Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucl Acids Res 2003; 31:298-303.
37. Shafer RW. Rationale and uses of a public HIV drug-resistance database. J Infect Dis 2006; 194 (Suppl. 1):S51-S58.
38. Wester CW, Okezie OA, Thomas AM, Bussmann H, Moyo S, Muzenda T, et al. Higher than expected rates of lactic acidosis among highly active antiretroviral therapy-treated women in Botswana: preliminary results from a large randomized clinical trial. J Acquir Immune Defic Syndr 2007; 46:318-322.